Dexamethasone intravitreal implant in vitrectomized versus nonvitrectomized eyes for treatment of patients with persistent diabetic macular edema

Marco Dutra Medeiros, Micol Alkabes, Rafael Navarro, José Garcia-Arumí, Carlos Mateo, Borja Corcóstegui

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Purpose: To compare the 6-month anatomic and best-corrected visual acuity (BCVA) response after sustained-release dexamethasone (DEX) intravitreal implant between nonvitrectomized and vitrectomized eyes with persistent diabetic macular edema (DME). Methods: Retrospective, comparative, and consecutive review of the medical records of 58 patients with decreased visual acuity, due to refractory DME, who underwent a single injection of Ozurdex between November 2010 and January 2012, at the Instituto de Microcirurgia Ocular, Barcelona, Spain. Then, we divided patients into 2 groups: 24 eyes who had undergone standard pars plana vitrectomy (vitrectomized group), and 34 eyes that were not operated on (nonvitrectomized group). Outcomes measured were BCVA and foveal thickness (FT) at baseline and at months 1, 3, and 6. Results: Twenty-four of 58 eyes had prior vitrectomy (41%). Statistically significant improvement in BCVA also was seen at 1 month after treatment with a DEX implant and at each subsequent follow-up visit, in either groups (P

Original languageEnglish
Pages (from-to)709-716
Number of pages8
JournalJournal of Ocular Pharmacology and Therapeutics
Volume30
Issue number9
DOIs
Publication statusPublished - 2014

Fingerprint

Macular Edema
Dexamethasone
Visual Acuity
Vitrectomy
Therapeutics
Temazepam
Spain
Medical Records
Injections

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Ophthalmology
  • Pharmacology
  • Medicine(all)

Cite this

Dexamethasone intravitreal implant in vitrectomized versus nonvitrectomized eyes for treatment of patients with persistent diabetic macular edema. / Medeiros, Marco Dutra; Alkabes, Micol; Navarro, Rafael; Garcia-Arumí, José; Mateo, Carlos; Corcóstegui, Borja.

In: Journal of Ocular Pharmacology and Therapeutics, Vol. 30, No. 9, 2014, p. 709-716.

Research output: Contribution to journalArticle

Medeiros, Marco Dutra ; Alkabes, Micol ; Navarro, Rafael ; Garcia-Arumí, José ; Mateo, Carlos ; Corcóstegui, Borja. / Dexamethasone intravitreal implant in vitrectomized versus nonvitrectomized eyes for treatment of patients with persistent diabetic macular edema. In: Journal of Ocular Pharmacology and Therapeutics. 2014 ; Vol. 30, No. 9. pp. 709-716.
@article{d0cdc55f3c504f7a8a347c16b6a3448b,
title = "Dexamethasone intravitreal implant in vitrectomized versus nonvitrectomized eyes for treatment of patients with persistent diabetic macular edema",
abstract = "Purpose: To compare the 6-month anatomic and best-corrected visual acuity (BCVA) response after sustained-release dexamethasone (DEX) intravitreal implant between nonvitrectomized and vitrectomized eyes with persistent diabetic macular edema (DME). Methods: Retrospective, comparative, and consecutive review of the medical records of 58 patients with decreased visual acuity, due to refractory DME, who underwent a single injection of Ozurdex between November 2010 and January 2012, at the Instituto de Microcirurgia Ocular, Barcelona, Spain. Then, we divided patients into 2 groups: 24 eyes who had undergone standard pars plana vitrectomy (vitrectomized group), and 34 eyes that were not operated on (nonvitrectomized group). Outcomes measured were BCVA and foveal thickness (FT) at baseline and at months 1, 3, and 6. Results: Twenty-four of 58 eyes had prior vitrectomy (41{\%}). Statistically significant improvement in BCVA also was seen at 1 month after treatment with a DEX implant and at each subsequent follow-up visit, in either groups (P",
author = "Medeiros, {Marco Dutra} and Micol Alkabes and Rafael Navarro and Jos{\'e} Garcia-Arum{\'i} and Carlos Mateo and Borja Corc{\'o}stegui",
year = "2014",
doi = "10.1089/jop.2014.0010",
language = "English",
volume = "30",
pages = "709--716",
journal = "Journal of Ocular Pharmacology and Therapeutics",
issn = "1080-7683",
publisher = "Mary Ann Liebert Inc.",
number = "9",

}

TY - JOUR

T1 - Dexamethasone intravitreal implant in vitrectomized versus nonvitrectomized eyes for treatment of patients with persistent diabetic macular edema

AU - Medeiros, Marco Dutra

AU - Alkabes, Micol

AU - Navarro, Rafael

AU - Garcia-Arumí, José

AU - Mateo, Carlos

AU - Corcóstegui, Borja

PY - 2014

Y1 - 2014

N2 - Purpose: To compare the 6-month anatomic and best-corrected visual acuity (BCVA) response after sustained-release dexamethasone (DEX) intravitreal implant between nonvitrectomized and vitrectomized eyes with persistent diabetic macular edema (DME). Methods: Retrospective, comparative, and consecutive review of the medical records of 58 patients with decreased visual acuity, due to refractory DME, who underwent a single injection of Ozurdex between November 2010 and January 2012, at the Instituto de Microcirurgia Ocular, Barcelona, Spain. Then, we divided patients into 2 groups: 24 eyes who had undergone standard pars plana vitrectomy (vitrectomized group), and 34 eyes that were not operated on (nonvitrectomized group). Outcomes measured were BCVA and foveal thickness (FT) at baseline and at months 1, 3, and 6. Results: Twenty-four of 58 eyes had prior vitrectomy (41%). Statistically significant improvement in BCVA also was seen at 1 month after treatment with a DEX implant and at each subsequent follow-up visit, in either groups (P

AB - Purpose: To compare the 6-month anatomic and best-corrected visual acuity (BCVA) response after sustained-release dexamethasone (DEX) intravitreal implant between nonvitrectomized and vitrectomized eyes with persistent diabetic macular edema (DME). Methods: Retrospective, comparative, and consecutive review of the medical records of 58 patients with decreased visual acuity, due to refractory DME, who underwent a single injection of Ozurdex between November 2010 and January 2012, at the Instituto de Microcirurgia Ocular, Barcelona, Spain. Then, we divided patients into 2 groups: 24 eyes who had undergone standard pars plana vitrectomy (vitrectomized group), and 34 eyes that were not operated on (nonvitrectomized group). Outcomes measured were BCVA and foveal thickness (FT) at baseline and at months 1, 3, and 6. Results: Twenty-four of 58 eyes had prior vitrectomy (41%). Statistically significant improvement in BCVA also was seen at 1 month after treatment with a DEX implant and at each subsequent follow-up visit, in either groups (P

UR - http://www.scopus.com/inward/record.url?scp=84930927564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930927564&partnerID=8YFLogxK

U2 - 10.1089/jop.2014.0010

DO - 10.1089/jop.2014.0010

M3 - Article

VL - 30

SP - 709

EP - 716

JO - Journal of Ocular Pharmacology and Therapeutics

JF - Journal of Ocular Pharmacology and Therapeutics

SN - 1080-7683

IS - 9

ER -